In October, GSK raised $1.1 billion, or £885.6 million, by selling some of its shares in Haleon, reducing its stake in the consumer healthcare business to around 7.4%.

Exc. Medicines.) That is why Sensodyne wanted to show its target audience that tooth sensitivity pain, and/or experiencing bleeding gums can be overcome with Sensodyne through the power of mobile ...

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

Despite pressure on consumer spending, consumers prioritise trusted brands for their health-related needs and Haleon is a ...

GSK initially retained a 12.9% stake in Haleon ... The company continues to own well-known household brands such as Sensodyne toothpaste, Panadol and Advil pain relief medication, and Centrum ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

Haleon’s household names such as Sensodyne and Paradontax toothpastes helped drive group revenue to £2.78bn. (Photo Illustration by Christof Koepsel/Getty Images) Consumer healthcare company ...

Subsequently, in July 2022, GSK spun off Haleon as an independent publicly traded company. Haleon owns popular brands such as Sensodyne, Centrum, Otrivin, and Eno. The recent sale is part of ...